UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
- 11 more years available »
Ranking
By Turnover
(€1.1 million)- 967th in Top Companies
- 97th in Health
- 83rd in Pharma
By Employees
(0)- 1029th in Top Companies
- 95th in Health
- 81st in Pharma
-
- 0
- €1.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 7:01am Bank of Ireland paves way for negative rates on accounts with over €1m
- 6:56am Air Corps bid for search and rescue services would result in job losses, union warns
- 6:56am FBD, ICG and Uniphar under fire over executive pay
- May 07 US jobs growth slows despite reopenings and vaccinations
- May 07 Regulator expects FBD to pay ‘all reasonable costs’ of publicans, court told